The once-daily tablet, plecanatide, is the company's first to win regulatory clearance.

The drug is also being evaluated to treat patients suffering from irritable bowel syndrome with constipation.

Synergy's plecanatide is expected to generate peak sales of $348.8 million by 2021, according to Thomson Reuters Cortellis. (Reporting by Divya Grover in Bengaluru; Additional reporting by Dipika Jain Bengaluru; Editing by Maju Samuel)

Only in India the healthcare financing is very small when compared to the financing by the other forces rather than the patient himself or herself paying out of pocket. Having 70-75% of the expenses as out-of-pocket, in my opinion, is not a right approach to managing healthcare in a country where the patients tend to sub-optimally purchase healthcare if he/she has to pay out-of-pocket.